Elevai Labs, Inc. (NASDAQ:ELAB – Get Free Report) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 868,700 shares, an increase of 859.9% from the August 15th total of 90,500 shares. Based on an average daily volume of 2,120,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 11.4% of the company’s stock are short sold.
Elevai Labs Stock Performance
Elevai Labs stock opened at $0.35 on Friday. Elevai Labs has a twelve month low of $0.22 and a twelve month high of $4.24. The company has a quick ratio of 0.54, a current ratio of 1.05 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $7.28 million and a P/E ratio of -0.95. The stock’s 50 day moving average is $0.38 and its 200 day moving average is $0.56.
Elevai Labs (NASDAQ:ELAB – Get Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($0.08) EPS for the quarter. Elevai Labs had a negative return on equity of 216.19% and a negative net margin of 191.96%. The company had revenue of $0.61 million during the quarter.
Institutional Investors Weigh In On Elevai Labs
Elevai Labs Company Profile
Elevai Labs, Inc, a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc and changed its name to Elevai Labs, Inc in December 2021.
Further Reading
- Five stocks we like better than Elevai Labs
- Are Penny Stocks a Good Fit for Your Portfolio?
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- Investing In Preferred Stock vs. Common Stock
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- How to Effectively Use the MarketBeat Ratings Screener
- MarketBeat Week in Review – 9/9 – 9/13
Receive News & Ratings for Elevai Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevai Labs and related companies with MarketBeat.com's FREE daily email newsletter.